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Expanding adipose tissue in obesity requires a great deal of angiogenesis to support increasing volumes of
tissue. A growing body of evidence indicates that inhibiting these blood vessels can result in substantial
weight loss, and now this has been demonstrated in nonhuman primates.Extremely skeptical. That is the best
description of my response to publica-
tions indicating that either diet-induced
or genetic forms of obesity could be re-
versed by giving inhibitors to blood vessel
formation. The first of these reports came
from Maria Rupnick and Judah Folkman,
who used agents that inhibit tumor growth
and found profound weight loss in mice
(Rupnick et al., 2002). The next of these
reports used a more sophisticated ap-
proach in an attempt to direct the inhibi-
tion of the blood vessels specifically to
adipose tissue. In an effort led by Wadih
Arap and Renata Pasqulini, they used
a technology called phage display that
had been designed to identify the signa-
tures of tumor-associated blood vessels
that might be different than other blood
vessels. However, they determined that
many tissues, including adipose tissue,
had unique properties. They were able to
identify short peptide sequences that
would selectively bind to the vasculature
of white adipose tissue, but not other
tissues they examined. As cancer re-
searchers, they took the next logical step.
They used this peptide and attached a
poison pill that would produce apoptosis
in the targeted blood vessels (Kolonin
et al., 2004). This targeted approach also
led to rapid and substantial weight loss
in mice. In their most recent manuscript
published in Science Translational Medi-
cine, this group has extended these
results to obese nonhuman primates,
showing substantial weight and body fat
loss after 28 days of treatment with this
peptide (Barnhart et al., 2011).
The reason for my skepticism toward
this approach centered on the assump-
tion that, whether untargeted or targeted,
reducing adipose tissue blood vessels
would impair adipose tissue function.
While obesity is a scourge to be fought
and is the direct result of expandingadipose tissue, the truth is that healthy
adipose tissue serves an important func-
tion to protect the rest of the body from
nutrients that, when stored in other tis-
sues such as muscle and liver, cause
metabolic dysfunction. The most obvious
example of this comes from humans
or mice who fail to make sufficient
adipocytes. While leaner, such individuals
nevertheless have severemetabolic prob-
lems, including liver steatosis, hyper-
lipidemia, and severe insulin resistance
(Huang-Doran and Savage, 2011). Thus,
it seemed likely that such an approach
that compromised adipose tissue func-
tion could result in leaner individuals
who were more at risk for metabolic
disease.
Ultimately, the data in mice and
nonhuman primates simply do not sup-
port my assumption. In nonhuman pri-
mates, weight loss is accompanied by
reduced insulin resistance (Barnhart et al.,
2011). In mice, our own work has dem-
onstrated that treatment with this pep-
tide results in rapid weight loss that is
primarily due to reduced intake, and it
is accompanied by metabolic improve-
ments (Kim et al., 2010). The important
point here is that the response to tar-
geting the adipose tissue vasculature is
the exact opposite of what is observed
when adipocytes are not present or are
pushed into apoptosis. While removal of
adipocytes is associated with increased
intake and decreased insulin sensitivity
(Pajvani et al., 2005), removal of the sup-
porting vasculature results in decreased
intake and increased insulin sensitivity
(Kim et al., 2010). The conclusion to be
drawn is that adipocytes are an important
source of signals to both the brain and
other tissues and that the removal of
those signals is deleterious. Targeting
the adipose tissue vasculature results in
changes in adipocyte communicationCell Metabolismthat promote weight loss and improved
metabolic regulation.
This work has opened up an entirely
unappreciated aspect of adipose tissue
biology that explores the intimate relation-
ship between adipocytes and their sup-
porting vasculature. More importantly,
understanding and manipulating this rela-
tionship has important therapeutic impli-
cations, given the potent effects of this
particular peptide. A crucial question is
whether this approach borrowed from
cancer treatment is going to be suffi-
ciently safe to be used in the growing
number of individuals suffering under
the burden of obesity and its comorbid
conditions. After all, treating cancer is
considerably different from treating a
chronic condition such as obesity. Cancer
patients are often under a short-term
threat, while obesity is a much longer-
term threat to an individual’s health. As
a consequence, the risk-benefit analysis
is considerably different. For example,
the specificity of the targeting is less of a
concern in cancer as compared to obesity
treatment. Imagine a peptide with 90%
targeting selectivity to the tumor. Given
that the plan would be to treat the cancer
patient for weeks or months, as long as
the tumor is being undermined faster
than normal tissue, and that normal tissue
can recover once treatment is terminated,
it can be a viable therapy. For the obese
patient who is likely to be taking such a
treatment for the better part of his or
her life, would 90% targeting selectivity
be sufficient to avoid adverse effects
on other tissues? Ninety-five percent?
Ninety-nine percent? This is a complex
question that will need to be answered
before we know whether this approach
will become therapy.
The important new insights driven
by the work with these targeted pep-
tides are an important advance in an15, January 4, 2012 ª2012 Elsevier Inc. 1
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Previewsenvironment where few effective treat-
ment strategies short of bariatric sur-
gery are available to help obese patients.
It is clear that more creative strategies
from a wider range of disciplines are
needed. To that end, further under-
standing of how adipose tissue signal-
ing is altered by various aspects of its
milieu, including the supporting blood
vessels, macrophages, and its extracel-
lular matrix, is necessary if we are to bring
more therapies to the large unmetmedical2 Cell Metabolism 15, January 4, 2012 ª2012need presented by increasing rates of
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While age-dependent stem cell decline is widely recognized as being a key component of organismal aging,
the underlying mechanisms remain elusive. In this issue of Cell Metabolism, Suomalainen and colleagues
provide evidence that mitochondrial mutation and associated reactive oxygen species can adversely impact
tissue-specific stem and progenitor cell function.Physiological aging invariably leads to
a loss in normal tissue maintenance and
reduced regenerative potential. The fact
that these processes are normally under
the functional purview of adult tissue-
specific stem cells implicates age-associ-
ated stem cell decline as a fundamental
contributor to the aging of tissues and
organisms. Indeed, the importance of
the stem cell compartment in contributing
to age-associated pathophysiology has
been demonstrated in a number of stud-
ies (Rossi et al., 2008). Consistent with
the inherent complexity of physiological
aging, the mechanistic basis for age-
related stem cell decline is similarly
complex, with evidence suggesting the
involvement of cellular, genetic, and epi-
genetic components (Rossi et al., 2008).
However, recent evidence from a number
of papers, including a paper by Suomalai-
nen and colleagues in this issue of CellMetabolism, suggests that accumulating
mitochondrial DNA damage may also be
an important contributor to somatic stem
cell decline with age.
Mitochondria are frequently referred
to as the cell’s ‘‘power plants’’ since
they play a fundamental role in the
production of adenosine triphosphate
(ATP) through oxidative phosphorylation
(OXPHOS). Most aerobic organisms use
some form of OXPHOS because it is
a highly efficient method for produc-
ing ATP; however, the downside of this
energy-producing pathway is that it also
leads to the production of reactive oxygen
species (ROS) that have the potential to
damage cellular macromolecules and, in
such a way, contribute to aging. Mito-
chondrial DNA (mtDNA) is believed to be
highly susceptible to oxidative damage
in part because of its proximity to the elec-
tron transport chain, but also becausemtDNA lacks protective histones. Accu-
mulation of damage in the mitochondrial
genome has been proposed to lead to
mitochondrial dysfunction and concomi-
tant cellular decline and, in such a way,
contribute to physiological aging (Har-
man, 1972). This long-held theory was
supported experimentally with the gener-
ation of mtDNA ‘‘mutator’’ mice bearing a
proofreading-deficient mtDNA polymer-
ase (POLG) that exhibit a spectrum of
degenerative phenotypes reminiscent of
aging (Kujoth et al., 2005; Trifunovic
et al., 2004). More recently, these mice
have also provided the necessary ex-
perimental tool to address how mtDNA
mutation accumulation impacts stem cell
function and to determine whether it
contributes to age-associated stem cell
decline.
Within mammalian tissues, aging has
been most comprehensively studied in
